

Clinical Policy: Helicobacter Pylori Serology Testing

Reference Number: LA.CP.MP.153

Date of Last Revision 10/2022

Coding Implications

Revision Log

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Helicobacter pylori (*H. pylori*) is the most prevalent chronic bacterial infection and is associated with peptic ulcer disease, chronic gastritis, gastric adenocarcinoma, and gastric mucosa associated lymphoid tissue (MALT) lymphoma. Noninvasive tests for the diagnosis of *H. pylori* include urea breath testing (UBT), stool antigen testing, and serology.¹

Policy/Criteria

- I. It is the policy of Louisiana Healthcare Connections that *H. pylori* serology testing is not medically necessary for diagnosing infection or evaluating treatment effectiveness.

Background

The most common causes of peptic ulcer disease (PUD) are *H. pylori* infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). *H. pylori* infection causes progressive functional and structural gastroduodenal damage.⁴ Accurate diagnosis of *H. pylori* infection is a crucial part in the effective management of many gastroduodenal diseases. Several invasive and non-invasive diagnostic tests are available for the detection of *H. pylori* and each test has its usefulness and limitations in different clinical situations.⁸

Urea breath tests and stool antigen tests are the most widely used non-invasive tests for identifying *H. pylori* infection, as well as most accurate. In addition, they can be used to confirm cure. Serologic tests are a convenient but less accurate alternative and cannot be used to confirm cure.²

The urea breath test is the noninvasive test of choice for the diagnosis of *H. pylori*, with high sensitivity (88% to 95%) and specificity (95% to 100%) for the detection of active *H. pylori* infections.⁴ Urea breath tests require the ingestion of urea labeled with the nonradioactive isotope carbon 13 or carbon 14. Specificity and sensitivity approach 100%. Urea breath testing is an option for test of cure and should be performed four to six weeks after completion of eradication therapy. Proton pump inhibitors (PPIs) must be stopped for at least two weeks before the test, and accuracy is lower in patients who have had distal gastrectomy.²

Stool antigen tests using monoclonal antibodies are as accurate as urea breath tests if a validated laboratory-based monoclonal test is used. Like urea breath tests, stool antigen tests detect only active infection and can also be used as a test of cure. PPIs should be stopped for two weeks before testing, but stool antigen tests are not as affected by PPI use.²

Serologic antibody testing detects immunoglobulin G specific to *H. pylori* in serum and cannot distinguish between an active infection and a past infection.² Most common serologic tests are based on an enzyme-linked immunosorbent assay (ELISA) technology. As with any test, prevalence of the *H. pylori* infection and the pretest probability influence the positive or negative predictive values. Overall, where the prevalence of *H. pylori* infection and the pretest probability

are low, the negative predictive value of a serologic test is high whereas false positives are more frequent, with the opposite in high prevalence/high pretest probability cases (i.e., the positive predictive value is high but there is increased prevalence of false negative results).⁴ Antibody testing cannot be used as a test of cure.²

American Society for Clinical Pathology

Per the American Society for Clinical Pathology, serologic evaluation of patients to determine the presence/absence of H. pylori infection is no longer considered clinically useful. Alternative noninvasive testing methods (e.g., the urea breath test and stool antigen test) exist for detecting the presence of the bacteria and have demonstrated higher clinical utility, sensitivity, and specificity.¹¹

The American Gastroenterological Association (AGA)

The AGA no longer recommends serology-based testing for diagnosing infection or evaluating treatment effectiveness as it is unable to distinguish between active infection and previous exposure to H. pylori, does not confirm eradication and has a poor positive predictive value when compared to active infection tests such as the urea breath test or stool antigen test.⁷

The American College of Gastroenterology

The American College of Gastroenterology states that all patients with active PUD, a past history of PUD (unless previous cure of H. pylori infection has been documented), low-grade gastric MALT lymphoma, or a history of endoscopic resection of early gastric cancer should be tested for H. pylori infection. In patients with uninvestigated dyspepsia who are under the age of 60 years and without alarm features, non-endoscopic testing for H. pylori infection is a consideration. Other indications to test patients for H. pylori infection may include, patients taking long-term low-dose aspirin, patients initiating chronic treatment with an NSAID, patients with unexplained iron deficiency anemia despite an appropriate evaluation and adults with idiopathic thrombocytopenic purpura. Any individual who tests positive should be offered eradication therapy. Patients with a history of PUD who have previously been treated for H. pylori infection should undergo eradication testing with a urea breath test or fecal antigen test.³

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage and may not support medical necessity. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
86677	Antibody; Helicobacter pylori

HCPCS Codes	Description
N/A	

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

ICD-10-CM Code	Description
N/A	

Reviews, Revisions, and Approvals	Date	Approval Date
Converted corporate to local policy.	08/15/2020	
Annual review; minor wording changing member to member/enrollee. Added “and may not support medical necessity” to coding implications section	10/22	1/14/23

References

1. Lamont JT. Indications and diagnostic tests for *Helicobacter pylori* infection. Nov 17. In: UpToDate, www.uptodate.com. Updated May 2, 2022. Accessed August 12, 2022
2. Fashner J, Gitu AC. Diagnosis and Treatment of Peptic Ulcer Disease and *H. pylori* Infection. *Am Fam Physician*. 2015;91(4):236 to 242
3. Chey WD, Leontiadis GI, Howden CW, Moss SF. Correction: ACG Clinical Guideline: Treatment of *Helicobacter pylori* infection. *Am J Gastroenterol* 2018;113(7):1102.; doi: 10.1038/ s41395-018-0132-6
4. Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: When and how to test for *Helicobacter pylori* infection. *Gastroenterol Res Pract*. 2016;2016:8463614. doi: 10.1155/2016/8463614.
5. Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. *Gastroenterology*. 2005;129(5):1753-. to 1755. doi:10.1053/j.gastro.2005.09.019
6. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of *Helicobacter pylori* infection: Current options and developments. *World J Gastroenterol*. 2015 Oct 28;21(40):11221- to 11235.. doi: 10.3748/wjg.v21.i40.11221.
7. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. *Gastroenterology*. 2005;129(5):1756-. to 1780. doi:10.1053/j.gastro.2005.09.020
8. Pourakbari B, Ghazi M, Mahmoudi S, et al. Diagnosis of *Helicobacter pylori* infection by invasive and noninvasive tests. *Braz J Microbiol*. 2013;44(3):795 to 798. Published 2013 Nov 15. doi: 10.1590/S1517-83822013005000052.
9. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of *Helicobacter pylori* infection: Current options and developments. *World J Gastroenterol*. 2015;21(40):11221to 11235. doi: 10.3748/wjg.v21.i40.11221
10. Girdalidze AM, Elisabedashvili GV, Sharvadze LG, Dzhorbenadze TA. *Georgian Med News*. 2013 Dec;(225):53 to60.
11. Choosing Wisely: Do not request serology for *H. pylori* - Use the stool antigen or breath tests instead. American Society for Clinical Pathology. <https://www.choosingwisely.org/clinician->

- [lists/american-society-clinical-pathology-serology-for-h-pylori/](#). Published September 14, 2016. Accessed August 11, 2022.
12. Pak K, Junga Z, Mertz A, Singla M. The Patterns and Associated Cost of Serologic Testing for *Helicobacter pylori* in the U.S. Military Health System [published correction appears in *Mil Med*. 2020 Dec 30;185(11-12):e2201]. *Mil Med*. 2020;185(9-10):e1417 to e1419. doi:10.1093/milmed/usaa141
 13. Katelaris P, Hunt R. World Gastroenterology Organisation Global Guidelines. *Helicobacter pylori*. <https://www.worldgastroenterology.org/guidelines/helicobacter-pylori/helicobacter-pylori-english> Published 2010 (Updated 2021). Accessed August 12, 2022.
 14. Dore MP, Pes GM. What Is New in *Helicobacter pylori* Diagnosis. An Overview. *J Clin Med*. 2021;10(10):2091. Published 2021 May 13. doi:10.3390/jcm10102091

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.

©2020 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.